Clinical trial
A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients
NCT00496704 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients
- Lead sponsor
- Yonsei University
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 31, 2007
- Completion date
- Not reported
- Enrollment
- 56 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer